Cathepsin B and uPAR regulate self-renewal of glioma-initiating cells through GLI-regulated Sox2 and Bmi1 expression

Carcinogenesis

Volumn 34, Issue 3, 2013, Pages 550-559

  Gopinath, Sreelatha ^a   Malla, RamaRao ^a   Alapati, Kiranmai ^a   Gorantla, Bharathi ^a   Gujrati, Meena ^a   Dinh, Dzung H ^a   Rao, Jasti S ^a  

^a UNIVERSITY OF ILLINOIS AT URBANA CHAMPAIGN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BMI1 PROTEIN; CATHEPSIN B; CD133 ANTIGEN; CYCLOPAMINE; MESSENGER RNA; NESTIN; SONIC HEDGEHOG PROTEIN; TRANSCRIPTION FACTOR GLI1; TRANSCRIPTION FACTOR GLI2; TRANSCRIPTION FACTOR SOX2; UROKINASE RECEPTOR;

ARTICLE; CANCER STEM CELL; CELL DIFFERENTIATION; CELL ISOLATION; CELL RENEWAL; CONTROLLED STUDY; DOWN REGULATION; GLIOMA CELL; GLIOMA INITIATING CELL; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN BINDING; PROTEIN EXPRESSION; UPREGULATION; WESTERN BLOTTING;

ANIMALS; ANTIGENS, CD; CATHEPSIN B; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SEPARATION; FEMALE; FLOW CYTOMETRY; GENE EXPRESSION; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE KNOCKDOWN TECHNIQUES; GLIOMA; GLYCOPROTEINS; HEDGEHOG PROTEINS; HUMANS; MICE; MICE, NUDE; NEOPLASM TRANSPLANTATION; NEOPLASTIC STEM CELLS; PEPTIDES; POLYCOMB REPRESSIVE COMPLEX 1; RECEPTORS, UROKINASE PLASMINOGEN ACTIVATOR; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; SOXB1 TRANSCRIPTION FACTORS; TRANSCRIPTION FACTORS; TRANSCRIPTIONAL ACTIVATION;

EID: 84874769390     PISSN: 01433334     EISSN: 14602180     Source Type: Journal    
DOI: 10.1093/carcin/bgs375     Document Type: Article

References (54)

1. Louis, D.N. et al. (2007) The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol., 114, 97-109.
2. Deorah, S. et al. (2006) Trends in brain cancer incidence and survival in the United States: Surveillance, Epidemiology, and End Results Program, 1973 to 2001. Neurosurg. Focus, 20, E1.
3. Galli, R. et al. (2004) Isolation and characterization of tumorigenic, stem-like neural precursors from human glioblastoma. Cancer Res., 64, 7011-7021.
4. Singh, S.K. et al. (2003) Identification of a cancer stem cell in human brain tumors. Cancer Res., 63, 5821-5828.
5. Singh, S.K. et al. (2004) Identification of human brain tumour initiating cells. Nature, 432, 396-401.
6. Dontu, G. et al. (2003) Stem cells in normal breast development and breast cancer. Cell Prolif., 36 (suppl 1), 59-72.
7. Kopper, L. et al. (2004) Tumor stem cells. Pathol. Oncol. Res., 10, 69-73.
8. Taipale, J. et al. (2001) The Hedgehog and Wnt signalling pathways in cancer. Nature, 411, 349-354.
9. Leis, O. et al. (2012) Sox2 expression in breast tumours and activation in breast cancer stem cells. Oncogene, 31, 1354-1365.
10. Nakatsugawa, M. et al. (2011) SOX2 is overexpressed in stem-like cells of human lung adenocarcinoma and augments the tumorigenicity. Lab Invest., 91, 1796-1804.
11. Park, I.K. et al. (2004) Bmi1, stem cells, and senescence regulation. J. Clin. Invest., 113, 175-179.
12. Dahmane, N. et al. (2001) The Sonic Hedgehog-Gli pathway regulates dorsal brain growth and tumorigenesis. Development, 128, 5201-5212.
13. Clement, V. et al. (2007) HEDGEHOG-GLI1 signaling regulates human glioma growth, cancer stem cell self-renewal, and tumorigenicity. Curr. Biol., 17, 165-172.
14. Ehtesham, M. et al. (2007) Ligand-dependent activation of the hedgehog pathway in glioma progenitor cells. Oncogene, 26, 5752-5761.
15. Fong, H. et al. (2008) Regulation of self-renewal and pluripotency by Sox2 in human embryonic stem cells. Stem Cells, 26, 1931-1938.
16. Masui, S. et al. (2007) Pluripotency governed by Sox2 via regulation of Oct3/4 expression in mouse embryonic stem cells. Nat. Cell Biol., 9, 625-635.
17. Suh, H. et al. (2007) In vivo fate analysis reveals the multipotent and selfrenewal capacities of Sox2+ neural stem cells in the adult hippocampus. Cell Stem Cell, 1, 515-528.
18. Gangemi, R.M. et al. (2009) SOX2 silencing in glioblastoma tumor-initiating cells causes stop of proliferation and loss of tumorigenicity. Stem Cells, 27, 40-48.
19. Ikushima, H. et al. (2009) Autocrine TGF-beta signaling maintains tumorigenicity of glioma-initiating cells through Sry-related HMG-box factors. Cell Stem Cell, 5, 504-514.
20. Schmitz, M. et al. (2007) Identification of SOX2 as a novel glioma-associated antigen and potential target for T cell-based immunotherapy. Br. J. Cancer, 96, 1293-1301.
21. Park, E.T. et al. (2008) Aberrant expression of SOX2 upregulates MUC5AC gastric foveolar mucin in mucinous cancers of the colorectum and related lesions. Int. J. Cancer, 122, 1253-1260.
22. Chen, Y. et al. (2008) The molecular mechanism governing the oncogenic potential of SOX2 in breast cancer. J. Biol. Chem., 283, 17969-17978.
23. Sanada, Y. et al. (2006) Histopathologic evaluation of stepwise progression of pancreatic carcinoma with immunohistochemical analysis of gastric epithelial transcription factor SOX2: comparison of expression patterns between invasive components and cancerous or nonneoplastic intraductal components. Pancreas, 32, 164-170.
24. Ferri, A.L. et al. (2004) Sox2 deficiency causes neurodegeneration and impaired neurogenesis in the adult mouse brain. Development, 131, 3805-3819.
25. Annovazzi, L. et al. (2011) SOX2 expression and amplification in gliomas and glioma cell lines. Cancer Genomics Proteomics, 8, 139-147.
26. Leung, C. et al. (2004) Bmi1 is essential for cerebellar development and is overexpressed in human medulloblastomas. Nature, 428, 337-341.
27. Vonlanthen, S. et al. (2001) The bmi-1 oncoprotein is differentially expressed in non-small cell lung cancer and correlates with INK4A-ARF locus expression. Br. J. Cancer, 84, 1372-1376.
28. Kim, T.Y. et al. (2006) Epigenomic profiling reveals novel and frequent targets of aberrant DNA methylation-mediated silencing in malignant glioma. Cancer Res., 66, 7490-7501.
29. Haupt, Y. et al. (1993) bmi-1 transgene induces lymphomas and collaborates with myc in tumorigenesis. Oncogene, 8, 3161-3164.
30. Matsui, W. et al. (2004) Characterization of clonogenic multiple myeloma cells. Blood, 103, 2332-2336.
31. Nowak, K. et al. (2006) BMI1 is a target gene of E2F-1 and is strongly expressed in primary neuroblastomas. Nucleic Acids Res., 34, 1745-1754.
32. Godlewski, J. et al. (2008) Targeting of the Bmi-1 oncogene/stem cell renewal factor by microRNA-128 inhibits glioma proliferation and selfrenewal. Cancer Res., 68, 9125-9130.
33. Bruggeman, S.W. et al. (2005) Ink4a and Arf differentially affect cell proliferation and neural stem cell self-renewal in Bmi1-deficient mice. Genes Dev., 19, 1438-1443.
34. Molofsky, A.V. et al. (2003) Bmi-1 dependence distinguishes neural stem cell self-renewal from progenitor proliferation. Nature, 425, 962-967.
35. Molofsky, A.V. et al. (2005) Bmi-1 promotes neural stem cell self-renewal and neural development but not mouse growth and survival by repressing the p16Ink4a and p19Arf senescence pathways. Genes Dev., 19, 1432-1437.
36. Zencak, D. et al. (2005) Bmi1 loss produces an increase in astroglial cells and a decrease in neural stem cell population and proliferation. J. Neurosci., 25, 5774-5783.
37. Valk-Lingbeek, M.E. et al. (2004) Stem cells and cancer; the polycomb connection. Cell, 118, 409-418.
38. Gondi, C.S. et al. (2006) RNA interference-mediated simultaneous downregulation of urokinase-type plasminogen activator receptor and cathepsin B induces caspase-8-mediated apoptosis in SNB19 human glioma cells. Mol. Cancer Ther., 5, 3197-3208.
39. Gondi, C.S. et al. (2007) Intraperitoneal injection of a hairpin RNAexpressing plasmid targeting urokinase-type plasminogen activator (uPA) receptor and uPA retards angiogenesis and inhibits intracranial tumor growth in nude mice. Clin. Cancer Res., 13, 4051-4060.
40. Lakka, S.S. et al. (2004) Inhibition of cathepsin B and MMP-9 gene expression in glioblastoma cell line via RNA interference reduces tumor cell invasion, tumor growth and angiogenesis. Oncogene, 23, 4681-4689.
41. Hemmati, H.D. et al. (2003) Cancerous stem cells can arise from pediatric brain tumors. Proc. Natl. Acad. Sci. U.S.A., 100, 15178-15183.
42. Dingli, D. et al. (2006) Successful therapy must eradicate cancer stem cells. Stem Cells, 24, 2603-2610.
43. Kamachi, Y. et al. (2000) Pairing SOX off: with partners in the regulation of embryonic development. Trends Genet., 16, 182-187.
44. Graham, V. et al. (2003) SOX2 functions to maintain neural progenitor identity. Neuron, 39, 749-765.
45. Lee, J. et al. (2006) Tumor stem cells derived from glioblastomas cultured in bFGF and EGF more closely mirror the phenotype and genotype of primary tumors than do serum-cultured cell lines. Cancer Cell, 9, 391-403.
46. Ben-Porath, I. et al. (2008) An embryonic stem cell-like gene expression signature in poorly differentiated aggressive human tumors. Nat. Genet., 40, 499-507.
47. Park, I.K. et al. (2003) Bmi-1 is required for maintenance of adult selfrenewing haematopoietic stem cells. Nature, 423, 302-305.
48. Liu, S. et al. (2006) Hedgehog signaling and Bmi-1 regulate self-renewal of normal and malignant human mammary stem cells. Cancer Res., 66, 6063-6071.
49. Takanaga, H. et al. (2009) Gli2 is a novel regulator of sox2 expression in telencephalic neuroepithelial cells. Stem Cells, 27, 165-174.
50. Hwang, Y.S. et al. (1992) Efficacy of once-daily felodipine monotherapy in systemic hypertension. Am. J. Cardiol., 69, 271-274.
51. Stecca, B. et al. (2005) Interference with HH-GLI signaling inhibits prostate cancer. Trends Mol. Med., 11, 199-203.
52. Eberl, M. et al. (2012) Hedgehog-EGFR cooperation response genes determine the oncogenic phenotype of basal cell carcinoma and tumour-initiating pancreatic cancer cells. EMBO Mol. Med., 4, 218-233.
53. Schnidar, H. et al. (2009) Epidermal growth factor receptor signaling synergizes with Hedgehog/GLI in oncogenic transformation via activation of the MEK/ERK/JUN pathway. Cancer Res., 69, 1284-1292.
54. Piccirillo, S.G. et al. (2006) Bone morphogenetic proteins regulate tumorigenicity in human glioblastoma stem cells. Ernst. Schering. Found. Symp. Proc., 5, 59-81.